$ATRA
Atara Biotherapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021023337 Filed on May 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $3.550M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.74M $16.14M $17.04M
YoY Change 4.11% -10.63% -11.34%
% of Gross Profit
Research & Development $64.06M $65.55M $57.66M
YoY Change 11.1% 6.34% 18.47%
% of Gross Profit
Depreciation & Amortization $2.220M $2.150M $1.950M
YoY Change 13.85% 13.16% 18.18%
% of Gross Profit
Operating Expenses $81.80M $81.70M $74.70M
YoY Change 9.51% 2.51% 10.03%
Operating Profit
YoY Change
Interest Expense -$90.00K $400.0K $1.190M
YoY Change -107.56% -67.21% -26.99%
% of Operating Profit
Other Income/Expense, Net -$90.00K $1.188M
YoY Change -107.58% -27.29%
Pretax Income -$78.34M -$81.30M -$73.51M
YoY Change 6.57% 3.59% 10.94%
Income Tax $10.00K
% Of Pretax Income
Net Earnings -$78.34M -$81.31M -$73.51M
YoY Change 6.57% 3.58% 10.95%
Net Earnings / Revenue -2206.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$856.5K -$952.3K -$1.201M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $435.2M $500.7M $214.6M
YoY Change 102.8% 93.25% -9.64%
Cash & Equivalents $151.1M $200.4M $70.20M
Short-Term Investments $284.1M $300.3M $144.4M
Other Short-Term Assets $19.50M $21.40M $14.60M
YoY Change 33.56% 53.96% 9.77%
Inventory
Prepaid Expenses
Receivables $9.600M $1.250M
Other Receivables $0.00 $0.00
Total Short-Term Assets $464.3M $523.3M $229.2M
YoY Change 102.58% 91.68% -8.61%
LONG-TERM ASSETS
Property, Plant & Equipment $51.47M $50.52M $54.44M
YoY Change -5.46% -6.75% -24.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $729.0K $827.0K $2.200M
YoY Change -66.86% 45.86% 29.41%
Total Long-Term Assets $65.33M $64.85M $70.30M
YoY Change -7.07% -7.3% -4.87%
TOTAL ASSETS
Total Short-Term Assets $464.3M $523.3M $229.2M
Total Long-Term Assets $65.33M $64.85M $70.30M
Total Assets $529.6M $588.1M $299.5M
YoY Change 76.84% 71.49% -7.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.36M $7.118M $8.100M
YoY Change 114.26% -10.61% 30.65%
Accrued Expenses $23.40M $3.016M $17.50M
YoY Change 33.71% -22.67% 22.38%
Deferred Revenue $35.50M $33.46M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $84.20M $82.90M $31.50M
YoY Change 167.3% 125.62% 25.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $100.0K $0.00
YoY Change -50.0% -100.0%
Other Long-Term Liabilities $2.026M $2.044M $15.20M
YoY Change -86.67% 59.44% 1188.14%
Total Long-Term Liabilities $2.026M $2.044M $15.20M
YoY Change -86.67% 59.44% 1188.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $84.20M $82.90M $31.50M
Total Long-Term Liabilities $2.026M $2.044M $15.20M
Total Liabilities $130.6M $125.8M $46.70M
YoY Change 179.66% 141.14% 14.48%
SHAREHOLDERS EQUITY
Retained Earnings -$1.203B -$1.125B -$891.5M
YoY Change 34.93% 37.49% 50.28%
Common Stock $1.602B $1.587B
YoY Change 43.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $399.0M $462.3M $252.8M
YoY Change
Total Liabilities & Shareholders Equity $529.6M $588.1M $299.5M
YoY Change 76.84% 71.49% -7.77%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$78.34M -$81.31M -$73.51M
YoY Change 6.57% 3.58% 10.95%
Depreciation, Depletion And Amortization $2.220M $2.150M $1.950M
YoY Change 13.85% 13.16% 18.18%
Cash From Operating Activities -$65.70M -$4.120M -$67.04M
YoY Change -2.01% -92.98% -4.5%
INVESTING ACTIVITIES
Capital Expenditures $2.197M -$600.0K $1.333M
YoY Change 64.82% -77.86% 67.46%
Acquisitions
YoY Change
Other Investing Activities $15.70M -$36.30M $40.31M
YoY Change -61.05% -1045.31% -41.06%
Cash From Investing Activities $13.50M -$36.89M $38.97M
YoY Change -65.36% -3364.6% -42.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.457M $24.28M
YoY Change -89.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.892M 178.8M 23.96M
YoY Change -87.93% 377.41% -1343.87%
NET CHANGE
Cash From Operating Activities -65.70M -4.120M -67.04M
Cash From Investing Activities 13.50M -36.89M 38.97M
Cash From Financing Activities 2.892M 178.8M 23.96M
Net Change In Cash -49.31M 137.8M -4.114M
YoY Change 1098.52% -785.13% -9.18%
FREE CASH FLOW
Cash From Operating Activities -$65.70M -$4.120M -$67.04M
Capital Expenditures $2.197M -$600.0K $1.333M
Free Cash Flow -$67.90M -$3.520M -$68.38M
YoY Change -0.7% -93.71% -3.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51471000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11930000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
729000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31811000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
290781000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1250000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19342000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2021Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
17355000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1601784000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
161000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1202916000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57659000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12786000
CY2021Q1 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
10655000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
35497000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84075000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
399037000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
529637000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12569000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2026000
CY2021Q1 us-gaap Liabilities
Liabilities
130600000
CY2021Q1 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
3552000
CY2020Q1 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84075000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
464307000
CY2021Q1 us-gaap Assets
Assets
529637000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
33455000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6057000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82901000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27795000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13041000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2044000
CY2020Q4 us-gaap Liabilities
Liabilities
125781000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83372000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83372000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1586616000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
296000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1124581000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
462339000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
588120000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64059000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17738000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17038000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
81797000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
74697000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78470000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73525000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91456000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61208000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
462339000
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1231000
CY2021Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1749000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12268000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-78335000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-135000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1395000
CY2020Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1330000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12644000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-73509000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
252822000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-78335000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-73509000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12268000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2222000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1949000
CY2021Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
373000
CY2020Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
364000
CY2021Q1 us-gaap Accretion Expense
AccretionExpense
21000
CY2020Q1 us-gaap Accretion Expense
AccretionExpense
19000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8360000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1828000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1888000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-38000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
209000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9555000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-590000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7672000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-5030000
CY2021Q1 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-5158000
CY2020Q1 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-514000
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1510000
CY2020Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-169000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6058000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2021Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-406000
CY2020Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-153000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65698000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67044000
CY2021Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
94055000
CY2020Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
56851000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
109751000
CY2020Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
97157000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2197000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1333000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13499000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38973000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2457000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24277000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1749000
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1330000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1231000
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1395000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
66000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75711000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152491000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71597000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1245000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1098000
CY2021Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
176000
CY2020Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
0
CY2021Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To Atm Facilities
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToATMFacilities
75000
CY2020Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To Atm Facilities
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToATMFacilities
112000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
90000
CY2021Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-17000
CY2020Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-165000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2892000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23957000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-49307000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4114000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201798000
CY2021Q1 atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
0
CY2020Q1 atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
281000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
10000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
17000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
435023000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
369665000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
369805000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
434828000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
64011000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
64032000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
64221000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
64322000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
433676000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
433837000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
499049000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
499345000
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
700000
CY2021Q1 us-gaap Interest Receivable
InterestReceivable
700000
CY2021Q1 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2020Q1 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
1400000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1400000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151097000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200404000
CY2021Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152491000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201798000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
73309000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
70193000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21838000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19676000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51471000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50517000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1900000
CY2021Q1 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2020Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2021Q1 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2020Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2021Q1 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2020Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2021Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.
CY2021Q1 atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20972916
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12268000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12644000

Files In Submission

Name View Source Status
0001564590-21-023337-index-headers.html Edgar Link pending
0001564590-21-023337-index.html Edgar Link pending
0001564590-21-023337.txt Edgar Link pending
0001564590-21-023337-xbrl.zip Edgar Link pending
atra-10q_20210331.htm Edgar Link pending
atra-10q_20210331_htm.xml Edgar Link completed
atra-20210331.xsd Edgar Link pending
atra-20210331_cal.xml Edgar Link unprocessable
atra-20210331_def.xml Edgar Link unprocessable
atra-20210331_lab.xml Edgar Link unprocessable
atra-20210331_pre.xml Edgar Link unprocessable
atra-ex101_42.htm Edgar Link pending
atra-ex102_118.htm Edgar Link pending
atra-ex103_119.htm Edgar Link pending
atra-ex311_11.htm Edgar Link pending
atra-ex312_9.htm Edgar Link pending
atra-ex321_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gey4yyuyarck000001.jpg Edgar Link pending
gey4yyuyarck000002.jpg Edgar Link pending
gey4yyuyarck000003.jpg Edgar Link pending
gey4yyuyarck000004.jpg Edgar Link pending
gm04ji223ugk000001.jpg Edgar Link pending
gm04ji223ugk000041.jpg Edgar Link pending
gm04ji223ugk000050.jpg Edgar Link pending
gm04ji223ugk000062.jpg Edgar Link pending
gm04ji223ugk000064.jpg Edgar Link pending
gm04ji223ugk000066.jpg Edgar Link pending
gm04ji223ugk000068.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending